DENVER, April 20, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the development of IMMU-114, a humanized monoclonal antibody directed against an immune response target, HLA-DR, for the potential treatment of cancer. Preclinical results on the evaluation of this antibody were presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR).
